Literature DB >> 35298659

Human Mesenchymal Stem/Stromal Cells in Immune Regulation and Therapy.

Éva Mezey1.   

Abstract

Studies of mesenchymal stem (or stromal) cells (MSCs) have moved from bedside to bench and back again. The stromal cells or fibroblasts are found in all tissues and participate in building the extracellular matrix (ECM). Bone marrow (BM)-derived MSCs have been studied for more than 50 years and have multiple roles. They function as stem cells and give rise to bone, cartilage, and fat in the BM (these are stem cells); support hematopoiesis (pericytes); and participate in sensing environmental changes and balancing pro- and anti-inflammatory conditions. In disease states, they migrate to sites of injury and release cytokines, hormones, nucleic acids depending on the microenvironment they find. Clinicians have begun to exploit these properties of BM, adipose tissue, and umbilical cord MSCs because they are easy to harvest and expand in culture. In this review, I describe the uses to which MSCs have been put, list ongoing clinical trials by organ system, and outline how MSCs are thought to regulate the innate and adaptive immune systems. I will discuss some of the reasons why clinical applications are still lacking. Much more work will have to be done to find the sources, doses, and culture conditions needed to exploit MSCs optimally and learn their healing potential. They are worth the effort. Published by Oxford University Press 2022.

Entities:  

Mesh:

Year:  2022        PMID: 35298659      PMCID: PMC8929448          DOI: 10.1093/stcltm/szab020

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  125 in total

1.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells.

Authors:  Margaret E Groh; Basabi Maitra; Emese Szekely; Omer N Koç
Journal:  Exp Hematol       Date:  2005-08       Impact factor: 3.084

Review 2.  Mechanisms of mesenchymal stromal cell immunomodulation.

Authors:  Karen English
Journal:  Immunol Cell Biol       Date:  2012-10-23       Impact factor: 5.126

Review 3.  Bone marrow stromal cells as immunomodulators. A primer for dermatologists.

Authors:  Krisztian Nemeth; Eva Mezey
Journal:  J Dermatol Sci       Date:  2014-10-31       Impact factor: 4.563

4.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.

Authors:  Guangwen Ren; Liying Zhang; Xin Zhao; Guangwu Xu; Yingyu Zhang; Arthur I Roberts; Robert Chunhua Zhao; Yufang Shi
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

5.  Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies.

Authors:  Hyung-Sik Kim; Ji Hyun Lee; Kyoung-Hwan Roh; Hee Jin Jun; Kyung-Sun Kang; Tae-Yoon Kim
Journal:  Stem Cells       Date:  2016-06-28       Impact factor: 6.277

Review 6.  Mesenchymal Stromal Cells and Cutaneous Wound Healing: A Comprehensive Review of the Background, Role, and Therapeutic Potential.

Authors:  Michael S Hu; Mimi R Borrelli; H Peter Lorenz; Michael T Longaker; Derrick C Wan
Journal:  Stem Cells Int       Date:  2018-05-20       Impact factor: 5.443

7.  Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.

Authors:  Halvard Bonig; Zyrafete Kuçi; Selim Kuçi; Shahrzad Bakhtiar; Oliver Basu; Gesine Bug; Mike Dennis; Johann Greil; Aniko Barta; Krisztián M Kállay; Peter Lang; Giovanna Lucchini; Raj Pol; Ansgar Schulz; Karl-Walter Sykora; Irene Teichert von Luettichau; Grit Herter-Sprie; Mohammad Ashab Uddin; Phil Jenkin; Abdulrahman Alsultan; Jochen Buechner; Jerry Stein; Agnes Kelemen; Andrea Jarisch; Jan Soerensen; Emilia Salzmann-Manrique; Martin Hutter; Richard Schäfer; Erhard Seifried; Shankara Paneesha; Igor Novitzky-Basso; Aharon Gefen; Neta Nevo; Gernot Beutel; Paul-Gerhardt Schlegel; Thomas Klingebiel; Peter Bader
Journal:  Cells       Date:  2019-12-05       Impact factor: 6.600

Review 8.  Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.

Authors:  Alexander Markov; Lakshmi Thangavelu; Surendar Aravindhan; Angelina Olegovna Zekiy; Mostafa Jarahian; Max Stanley Chartrand; Yashwant Pathak; Faroogh Marofi; Somayeh Shamlou; Ali Hassanzadeh
Journal:  Stem Cell Res Ther       Date:  2021-03-18       Impact factor: 6.832

9.  Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).

Authors:  Peter Bader; Zyrafete Kuçi; Shahrzad Bakhtiar; Oliver Basu; Gesine Bug; Michael Dennis; Johann Greil; Aniko Barta; Krisztián M Kállay; Peter Lang; Giovanna Lucchini; Raj Pol; Ansgar Schulz; Karl-Walter Sykora; Irene von Luettichau; Grit Herter-Sprie; Mohammad Ashab Uddin; Phil Jenkin; Abdulrahman Alsultan; Jochen Buechner; Jerry Stein; Agnes Kelemen; Andrea Jarisch; Jan Soerensen; Emilia Salzmann-Manrique; Martin Hutter; Richard Schäfer; Erhard Seifried; Thomas Klingebiel; Halvard Bonig; Selim Kuçi
Journal:  Bone Marrow Transplant       Date:  2018-01-29       Impact factor: 5.483

View more
  2 in total

Review 1.  Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.

Authors:  Saman Yasamineh; Hesam Ghafouri Kalajahi; Pooneh Yasamineh; Omid Gholizadeh; Hamed Rahmani Youshanlouei; Saeed Karimi Matloub; Masoud Mozafari; Elham Jokar; Yalda Yazdani; Mehdi Dadashpour
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

Review 2.  Current regenerative medicine-based approaches for skin regeneration: A review of literature and a report on clinical applications in Japan.

Authors:  Yusuke Shimizu; Edward Hosea Ntege; Hiroshi Sunami
Journal:  Regen Ther       Date:  2022-06-15       Impact factor: 3.651

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.